Human FOXP3 Methylation Panel to bisulfite sequencing of 20 genes and 141 CpG sites including FOXP3

Regulatory T-cells (Tregs) prevent autoimmune disease by inhibiting self-reactive T-cells. Tregs are known to exhibit a unique epigenome and express the transcription factor FOXP3, which is a biomarker that distinguishes Tregs from other non-regulatory T-cells. Our FOXP3 panel is a set of validated DNA methylation assays targeting genes that exhibit unique methylation profiles in Tregs.

The FOXP3 Methylation Assays cover a total of 20 human gene regions, 11 mouse gene regions, 1 rhesus monkey gene region. We can analyze the entire panel using targeted Next-Gen Bisulfite sequencing or analyze a select PCR region on Next-Gen or Pyrosequencing. The panel is customizable to exclude or include any other target regions of your interest.

Platform: Targeted Next-Gen Bisulfite Sequencing Pyrosequencing
Species: Human (Homo sapiens)
Stats: 4 multiplex PCRs, 20 genes, 29 assays, 141 CpGs, 4714 bp
Genes: 20 Genes human FOXP3 Methylation Panel

Please contact us at for specific academic pricing.

Background

Forkhead-box protein P3 (Foxp3) is a major transcription factor that is necessary for induction of the immunosuppressive function of regulatory T cells (Tregs). It is considered to be the most specific marker for Tregs in tumors, with its expression leading to poor survival rates in some types of cancer and improved survival rates in other types. Studies have shown that epigenetic modifications contribute to the stable expression of FOXP3 and other molecules associated with Treg cell function. These modifications include demethylation of CpG sites in the conserved non-coding sequence 2 (CNS2), Treg specific demethylated region (TSDR), proximal promoter, and upstream enhancer regions of the gene. Understanding the epigenetic regulation of FOXP3 and associated genes is critical in developing new approaches to autoimmune disease and cancer treatment.